Status: Recruiting
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Participants needed: 256
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Updated: Jun 2, 2026Locations: 13
Eligibility criteria
Age 18-75 years [+10]
Currently on a statin or any statin exposure within 24 weeks prior to consent. [+52]